New Potential Personalized Medicine Platform

p-medicine project, launched in February this year, is a 4-year Integrated project aiming at developing a new and state-of-the-art IT platform for personalized medicine. The researchers elaborated the first deliverables according to the agreed 'Description of Work', they identified and described motivated use case scenarios by underlining the p-medicine platform's end user needs and requirements.

"It is the purpose of p-medicine to deliver an architecture that will allow to drive medicine to more individualized treatments based on exploiting the vast amount of heterogeneous data of single patients by software, services, tools and models that will support physicians in decision making in their daily care of patients," said p-medicine project coordinator Prof. Dr. Norbert Graf, Director of the Department of Pediatric Oncology and Hematology, Saarland University (Germany).

"All presented use-case scenarios have been actively discussed and only the mutually agreed versions have been considered," added Prof. Graf, who helped elaborate the first project deliverables while contributing and coordinating the input from all project partners.

"Project partners demonstrated a strong commitment and an active enrolment. The p-medicine project is an interdisciplinary and collaborative research activity. One of the learnt lessons is: we are in the right direction with high skilled and experienced partners," concluded Prof. Graf.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to enable support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized treatment of cancer. p-medicine unifies European experts in different fields (clinicians, biologists, IT-specialists, ethical and legal experts) to develop and exploit data and tools that support translational research in every aspect.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
The European Integrated Project p-medicine is supported by the European Commission under the 7th Framework Programme, Grant agreement number 270089.

Most Popular Now

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...